[Peijia Bio] PL001 (CD19 CAR-T) Efficacy Passes Phase II Interim Analysis with Statistical Significance
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Peijia Bio's CAR-T therapy PL001 achieved significant success in its Phase II interim analysis for B-cell lymphoma, paving the way for accelerated NDA approval in Taiwan.